ReviewCurrent opinion in chemical biology2009
Emerging targets for antidepressant therapies.
Review in Current opinion in chemical biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Effectiveness of noninvasive brain stimulation in the treatment of anxiety disorders: a meta-analysis of sham or behaviour-controlled studies.Journal of psychiatry & neuroscience : JPNPooled it
- Cholinergic basal forebrain modulation of glymphatic function: implications for depression.Translational psychiatry · 2026Article
- Ameliorative Effects of Nypa fruticans Leaf Extract on Anxiety and Depression: Evidence From In Vivo and In Silico Studies.BioMed research international · 2026Article
- Neuropharmacological Effects of Terpenoids on Preclinical Animal Models of Psychiatric Disorders: A Review.Antioxidants (Basel, Switzerland) · 2022Review
- 17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats.Psychopharmacology · 2020Article
- Phytochemical Profile and Antidepressant Effect ofInternational journal of molecular sciences · 2019Article
- Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- Forebrain glucocorticoid receptor gene deletion attenuates behavioral changes and antidepressant responsiveness during chronic stress.Brain research · 2014Article
- Effects of omega-3 on behavioral and biochemical parameters in rats submitted to chronic mild stress.Metabolic brain disease · 2014Article
- Article
- Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.Recent patents on CNS drug discovery · 2012Article
- Boosting serotonin in the brain: is it time to revamp the treatment of depression?Journal of psychopharmacology (Oxford, England) · 2012Article
- Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the Flinders Sensitive Line rat: a genetic rodent model of depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Article
- Reconsidering anhedonia in depression: lessons from translational neuroscience.Neuroscience and biobehavioral reviews · 2011Review
- The folic acid endophenotype and depression in an elderly population.The journal of nutrition, health & aging · 2010Article
- Linking molecules to mood: new insight into the biology of depression.The American journal of psychiatry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite adequate antidepressant monotherapy, the majority of depressed patients do not achieve remission. Even optimal and aggressive therapy leads to a substantial number of patients who show minimal and often only transient improvement. In order to address this substantial problem of treatment-resistant depression, a number of novel targets for antidepressant therapy have emerged as a consequence of major advances in the neurobiology of depression. Three major approaches to uncover novel therapeutic interventions are: first, optimizing the modulation of monoaminergic neurotransmission; second, developing medications that act upon neurotransmitter systems other than monoaminergic circuits; and third, using focal brain stimulation to directly modulate neuronal activity. We review the most recent data on novel therapeutic compounds and their antidepressant potential. These include triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, and dopamine receptor agonists. Compounds affecting extra-monoamine neurotransmitter systems include CRF(1) receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Focal brain stimulation therapies include vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.